{"id":32277,"date":"2025-04-23T15:51:39","date_gmt":"2025-04-23T07:51:39","guid":{"rendered":"https:\/\/flcube.com\/?p=32277"},"modified":"2025-04-23T15:51:40","modified_gmt":"2025-04-23T07:51:40","slug":"united-innomed-closes-rmb-100-million-series-b-funding-for-heart-failure-devices","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32277","title":{"rendered":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices"},"content":{"rendered":"\n<p>Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.<\/p>\n\n\n\n<p><strong>Company and Product Pipeline<\/strong><br>Founded in 2020, United InnoMed specializes in closed-loop neuromodulation systems for heart failure patients. Its pipeline includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic Heart Failure System:<\/strong> A long-term implantable device combining cardiac resynchronization therapy (CRT) with hemodynamic monitoring.<\/li>\n\n\n\n<li><strong>Acute Decompensated HF System:<\/strong> A transient electrical stimulation device designed for hospitalized patients requiring circulatory support.<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Progress and Future Outlook<\/strong><br>Both systems have completed GLP-compliant animal studies and are preparing for NMPA-registered clinical trials in China. This funding milestone positions United InnoMed to advance its innovative solutions for heart failure management.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,199,20,4022],"class_list":["post-32277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cvd","tag-eli-lilly","tag-finance","tag-united-innomed"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32277\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32277\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T07:51:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T07:51:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices\",\"datePublished\":\"2025-04-23T07:51:39+00:00\",\"dateModified\":\"2025-04-23T07:51:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2307.webp\",\"keywords\":[\"CVD\",\"Eli Lilly\",\"Finance\",\"United InnoMed\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32277#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32277\",\"name\":\"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2307.webp\",\"datePublished\":\"2025-04-23T07:51:39+00:00\",\"dateModified\":\"2025-04-23T07:51:40+00:00\",\"description\":\"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32277\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2307.webp\",\"width\":1080,\"height\":608,\"caption\":\"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32277#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32277","og_locale":"en_US","og_type":"article","og_title":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices","og_description":"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.","og_url":"https:\/\/flcube.com\/?p=32277","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-23T07:51:39+00:00","article_modified_time":"2025-04-23T07:51:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32277#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32277"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices","datePublished":"2025-04-23T07:51:39+00:00","dateModified":"2025-04-23T07:51:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32277"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32277#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","keywords":["CVD","Eli Lilly","Finance","United InnoMed"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32277#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32277","url":"https:\/\/flcube.com\/?p=32277","name":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32277#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32277#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","datePublished":"2025-04-23T07:51:39+00:00","dateModified":"2025-04-23T07:51:40+00:00","description":"Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company\u2019s heart failure management systems.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32277#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32277"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32277#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","width":1080,"height":608,"caption":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32277#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32277"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32277\/revisions"}],"predecessor-version":[{"id":32280,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32277\/revisions\/32280"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32279"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}